Cilostazol for Secondary Stroke Prevention
暂无分享,去创建一个
T. Turan | S. Johnston | J. Wardlaw | M. Lansberg | K. Sheth | J. Elm | A. D. de Havenon | K. Toyoda | A. Shoamanesh | K. Johnston | O. Williams | Tracy E. Madsen
[1] J. Choi,et al. Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study. , 2011, Clinical therapeutics.
[3] R. Zitnik,et al. cAMP inhibition of interleukin-1-induced interleukin-6 production by human lung fibroblasts. , 1993, The American journal of physiology.
[4] Yuan-Han Yang,et al. Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study , 2017, Neurotherapeutics.
[5] N. Satoh‐Asahara,et al. Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer’s Disease , 2020, International journal of molecular sciences.
[6] Yu Kyeong Kim,et al. Efficacy of Cilostazol Administration in Alzheimer’s Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study , 2019, Neurotherapeutics.
[7] J. Wardlaw,et al. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions , 2015, International journal of stroke : official journal of the International Stroke Society.
[8] J. Wardlaw,et al. Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial , 2019, EClinicalMedicine.
[9] K. Ono,et al. Pharmacological Potential of Cilostazol for Alzheimer’s Disease , 2019, Front. Pharmacol..
[10] Hea‐Young Cho,et al. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. , 2010, British journal of clinical pharmacology.
[11] Y. Hung,et al. Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial , 2014, Endocrine.
[12] J. Wardlaw,et al. Protocol: The Lacunar Intervention Trial 2 (LACI-2). A trial of two repurposed licenced drugs to prevent progression of cerebral small vessel disease , 2020, European stroke journal.
[13] Diane Lacaille,et al. Validity of Diagnostic Codes for Acute Stroke in Administrative Databases: A Systematic Review , 2015, PloS one.
[14] H. Kamel,et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. , 2021, Stroke.
[15] J. Wardlaw,et al. Cilostazol for Secondary Prevention of Stroke and Cognitive Decline , 2020, Stroke.
[16] J. A. Herd,et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. , 1998, Journal of vascular surgery.
[17] Yongge Liu,et al. Comparison of the Effects of Cilostazol and Milrinone on cAMP-PDE Activity, Intracellular cAMP and Calcium in the Heart , 2002, Cardiovascular Drugs and Therapy.
[18] H. Diener,et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.
[19] Vivian Gu,et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. , 2008, The New England journal of medicine.
[20] Sheng Wang,et al. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. , 2000, Journal of cardiovascular pharmacology.
[21] C. Grines,et al. Coronary Stent Restenosis in Patients Treated With Cilostazol , 2005, Circulation.
[22] J. Boissel,et al. Phosphodiesterase III inhibitors for heart failure. , 2005, The Cochrane database of systematic reviews.
[23] K. Kotsa,et al. Efficacy and Safety of Adjunctive Cilostazol to Clopidogrel‐Treated Diabetic Patients With Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events , 2020, Journal of the American Heart Association.
[24] A. Kesselheim,et al. Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997 , 2021, Journal of pharmaceutical policy and practice.
[25] P. Dobesh,et al. Pharmacologic Therapy for Intermittent Claudication , 2009, Pharmacotherapy.
[26] J. Wardlaw,et al. Effects of Isosorbide Mononitrate and/or Cilostazol on Hematological Markers, Platelet Function, and Hemodynamics in Patients With Lacunar Ischaemic Stroke: Safety Data From the Lacunar Intervention-1 (LACI-1) Trial , 2019, Front. Neurol..
[27] Rian,et al. A DOSE-DEPENDENT INCREASE IN MORTALITY WITH VESNARINONE AMONG PATIENTS WITH SEVERE HEART FAILURE , 2000 .
[28] R. Carare,et al. Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid , 2014, Annals of clinical and translational neurology.
[29] C. Jang,et al. Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites , 2018, European Journal of Clinical Pharmacology.
[30] H. Milani,et al. Cilostazol but not sildenafil prevents memory impairment after chronic cerebral hypoperfusion in middle-aged rats , 2015, Behavioural Brain Research.
[31] W. Forbes,et al. Relative Bioavailability and Effects of a High Fat Meal on Single Dose Cilostazol Pharmacokinetics , 1999, Clinical pharmacokinetics.
[32] P. Hamet,et al. Vascular smooth muscle cell proliferation and its therapeutic modulation in hypertension. , 1991, American heart journal.
[33] T. Tani,et al. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. , 1990, Thrombosis research.
[34] A. Terashi,et al. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. , 2000, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[35] Y. Taniyama,et al. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. , 2000, Hypertension.
[36] Y. Kimura,et al. [Research and development of cilostazol: an antiplatelet agent]. , 2000, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[37] Yongge Liu,et al. Cilostazol as a unique antithrombotic agent. , 2003, Current pharmaceutical design.
[38] J. Roberts,et al. Intravenous Colchicine in the Management of Gouty Arthritis * , 1953, Annals of the rheumatic diseases.
[39] A. Weyrich,et al. Targeting phosphodiesterases in anti-platelet therapy. , 2012, Handbook of experimental pharmacology.
[40] A. Roso-Llorach,et al. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany , 2017, Pharmacoepidemiology and drug safety.
[41] K. Kawahira,et al. Effect of Cilostazol Administration on Cerebral Hemodynamics and Rehabilitation Outcomes in Poststroke Patients , 2011, The International journal of neuroscience.
[42] A. Kesselheim,et al. Incentives for drug development--the curious case of colchicine. , 2010, The New England journal of medicine.
[43] Y. Nakaya,et al. Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta. , 2001, Life sciences.
[44] C. Coffey,et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. , 2012, The New England journal of medicine.
[45] Y. Kondo,et al. Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients Within 48 Hours of Symptom Onset , 2019, Journal of the American Heart Association.
[46] K. Seung,et al. A randomized comparison study assessing the impact of cilostazol on the heart rate and arrhythmias by 24-hour ambulatory holter electrocardiographic monitoring after drug-eluting stent implantation for coronary artery disease. , 2015, Journal of atherosclerosis and thrombosis.
[47] D. DeMets,et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.
[48] P. Damman,et al. P2Y12 platelet inhibition in clinical practice , 2011, Journal of Thrombosis and Thrombolysis.
[49] N. Chattipakorn,et al. Phosphodiesterase-3 inhibitor (cilostazol) attenuates oxidative stress-induced mitochondrial dysfunction in the heart , 2014, Journal of Geriatric Cardiology.
[50] A. M. Lefer,et al. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation. , 1980, Circulation.
[51] R. Lewis,et al. Confounding by Indication in Clinical Research. , 2016, JAMA.
[52] M. Hiratsuka,et al. Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. , 2007, Drug metabolism and disposition: the biological fate of chemicals.
[53] Liping Liu,et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. , 2013, The New England journal of medicine.
[54] N. A. V. Motta,et al. Cilostazol exerts antiplatelet and anti‐inflammatory effects through AMPK activation and NF‐kB inhibition on hypercholesterolemic rats , 2016 .
[55] R. Conwit,et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High‐Risk TIA , 2018, The New England journal of medicine.
[56] S. Goto. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. , 2005, Atherosclerosis. Supplements.
[57] Kyungsoo Park,et al. Population pharmacodynamics of cilostazol in healthy Korean subjects , 2018, Translational and clinical pharmacology.
[58] Stephani Correia Brazão,et al. Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target , 2020, International Immunopharmacology.
[59] M. Hagiwara,et al. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. , 1988, Pharmacology.
[60] U. Ikeda,et al. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. , 1996, European journal of pharmacology.
[61] C. Pratt. Analysis of the cilostazol safety database. , 2001, The American journal of cardiology.
[62] M. Koga,et al. Small but Steady Steps in Stroke Medicine in Japan , 2019, Journal of the American Heart Association.
[63] K. Yasunaga,et al. Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease. , 1985, Arzneimittel-Forschung.
[64] G. Hankey. CSPS.com Trial of Adding Cilostazol to Antiplatelet Therapy to Reduce Recurrent Stroke , 2019, Stroke.
[65] Seong-Joon Lee,et al. Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique , 2017, BMC Neurology.
[66] J. Crouse,et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[67] K. Goa,et al. Cilostazol: a review of its use in intermittent claudication. , 2003, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[68] D. Mikhailidis,et al. Cilostazol for intermittent claudication. , 2014, The Cochrane database of systematic reviews.
[69] A. Algra,et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial , 2006, The Lancet.
[70] Yongge Liu,et al. New Mechanism of Action for Cilostazol: Interplay Between Adenosine and Cilostazol in Inhibiting Platelet Activation , 2002, Journal of cardiovascular pharmacology.
[71] B. Kim,et al. Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial , 2018, The Lancet Neurology.
[72] Jean-Baptiste Michel,et al. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. , 2012, Cardiovascular research.
[73] W. Hiatt,et al. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). , 2008, Journal of vascular surgery.
[74] Sadao Takahashi,et al. Effect of Cilostazol, a Cyclic AMP Phosphodiesterase Inhibitor, on the Proliferation of Rat Aortic Smooth Muscle Cells in Culture , 1992, Journal of cardiovascular pharmacology.
[75] M. Murata,et al. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study. , 1987, Arzneimittel-Forschung.
[76] S. Kwon,et al. Cilostazol Research in Asia: Can it Be Applied to European and American Patients? , 2015, International journal of stroke : official journal of the International Stroke Society.
[77] Toyoki Mori,et al. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. , 2006, Atherosclerosis.
[78] H. Hidaka,et al. Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. , 1992, Advances in second messenger and phosphoprotein research.
[79] H. Hanyu,et al. Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: A pilot study , 2013, Geriatrics & gerontology international.
[80] H. Hirayama. Cilostazol , 2018, Reactions Weekly.
[81] S. Schneider,et al. 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(11):5577–5582 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2004-0603 Interleukin-6 Regulates Human Adipose Tissue Lipid Metabolism and Leptin Produc , 2022 .
[82] Y. T. Lee,et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. , 2001, Atherosclerosis.
[83] J. Molnar,et al. Comparison of On-Treatment Platelet Reactivity Between Triple Antiplatelet Therapy With Cilostazol and Standard Dual Antiplatelet Therapy in Patients Undergoing Coronary Interventions , 2013, Journal of cardiovascular pharmacology and therapeutics.
[84] A. Kesselheim,et al. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population , 2015, Journal of General Internal Medicine.
[85] Kortaro Tanaka,et al. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial , 2019, The Lancet Neurology.
[86] P. Thompson,et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. , 2003, The American journal of cardiology.
[87] S. Johnston,et al. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. , 2020, The New England journal of medicine.
[88] Chia‐Hsuin Chang,et al. Risk of Heart Failure Hospitalization Associated With Cilostazol in Diabetes: A Nationwide Case–Crossover Study , 2019, Front. Pharmacol..
[89] G. Nuki,et al. A concise history of gout and hyperuricemia and their treatment , 2006, Arthritis research & therapy.
[90] Nicole J Asal,et al. Effect of cilostazol in treating diabetes-associated microvascular complications , 2017, Endocrine.
[91] H. Fukuyama,et al. A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol , 2016, Alzheimer's & dementia.
[92] P. Gresele,et al. Anti-platelet therapy: phosphodiesterase inhibitors. , 2011, British journal of clinical pharmacology.